Hydroxychloroquine Sulfate Ipca Laboratories (Hydroxychloroquine Sulfate)

Hydroxychloroquine sulfate is used in several disease categories, primarily infectious and autoimmune disorders.

• Malaria: Reduces parasite replication and alleviates acute febrile episodes.
• Rheumatoid arthritis: Decreases joint inflammation and slows disease progression.
• Systemic lupus erythematosus: Controls disease activity and reduces flare frequency.

• Hydroxychloroquine sulfate interferes with the parasite's ability to detoxify heme by inhibiting heme polymerization, leading to toxic heme accumulation. In immune cells, it raises lysosomal pH, impairing antigen processing and decreasing cytokine production, thereby modulating the inflammatory response.

Hydroxychloroquine sulfate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Retinal toxicity: risk of irreversible vision loss with prolonged therapy.
• Cardiac arrhythmias: QT prolongation and rare conduction disturbances.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing hydroxychloroquine sulfate, several precautions should be observed to minimize risks.

• Baseline eye exam: conduct ophthalmologic assessment before treatment and annually thereafter.
• Cardiac monitoring: evaluate ECG for QT interval in patients with cardiac risk factors.
• G6PD deficiency: screen patients to avoid hemolytic anemia.
• Pregnancy: consider risk‑benefit; drug is Category B but use only if clearly needed.
• Drug interactions: review concomitant medications that may prolong QT or affect metabolism.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Hydroxychloroquine sulfate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Azithromycin or other QT‑prolonging agents: increased risk of cardiac arrhythmias.
• Digoxin: may raise serum digoxin levels, leading to toxicity.
• Cyclosporine: enhanced hydroxychloroquine exposure, potential toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase plasma concentrations.
• Insulin or oral hypoglycemics: heightened risk of hypoglycemia.